Westin, S. N., Moore, K. N., Guy, M., Jordan, S., McHale, M., Miller, E., Ozair, S., Resnick, K. E., Szabolcs, M., Zagouri, F., Wimberger, P., Bodnar, L., Kamiura, S., Wuliang, W., Donnelly, C., Liu, X., Stewart, R., Wang, Y., Iyer, S., Nieuwenhuysen, E. V. (2025). Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.5512